Predict your next investment

Corporation
HEALTHCARE | Drug Development
avistapharma.com

See what CB Insights has to offer

Founded Year

2017

Stage

Acquired | Acquired

Valuation

$0000 

About Avista Pharma Solutions

Avista Pharma Solutions is a contract development, manufacturing, and testing organization formed through carve-outs of the CMC business of Array BioPharma and contract services business of Scynexis. The company offers a broad suite of scientifically differentiated services ranging from early stage discovery, API and Drug Product development and cGMP manufacturing to stand-alone analytical and microbiology testing support.

Avista Pharma Solutions Headquarter Location

3501 Tricenter Blvd Suite C

Durham, North Carolina, 27713,

United States

919-544-8600

Latest Avista Pharma Solutions News

Avid Bioservices Appoints Timothy Compton as Chief Commercial Officer

Jan 8, 2020

| Source: Avid Bioservices, Inc TUSTIN, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO ) (NASDAQ: CDMOP ), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Timothy Compton as chief commercial officer. Mr. Compton is an accomplished professional who possesses extensive experience in commercial operations, including sales team management, business development, marketing and corporate development. In his new role, he will be responsible for driving the continued growth of Avid’s CDMO business, including the ongoing expansion of the company’s commercial and clinical client base. Mr. Compton is replacing Tracy Kinjerski, who has left the company to pursue other opportunities. Mr. Compton most recently served as senior director of sales and business development for Cambrex Corporation, a leading small molecule CDMO, where he managed the company’s Western North America and Asia Pacific CDMO sales and business development team. Following Cambrex’s 2019 acquisition of Avista Pharma Solutions, he played a key role in transitioning Avista’s commercial operations practices to Cambrex. Prior to its sale to Cambrex, Mr. Compton was vice president of sales for Avista, overseeing sales, business development and business operations across all the company’s service offerings, driving significant year-over-year revenue growth. Mr. Compton held multiple senior level positions with AAIPharma Services Corporation, a CDMO now named Alcami, including executive director of alliance management and  executive director of business development. His career has also included tenures with a range of life science companies including Baypoint Biosystems, N.V. Organon, Kadmus Pharmaceuticals and Atairgin Technologies. “We are excited to have Tim join the Avid team and contribute his broad CDMO industry experience to the continued growth and expansion of our business. His track record of driving impressive sales and revenue growth in this space positions him ideally to serve as Avid’s chief commercial officer,” said Rick Hancock, interim president and chief executive officer of Avid. “On behalf of the company, I’d also like to express my gratitude to Tracy Kinjerski for the important contributions that she made during her time with Avid. We wish her well in all of her future endeavors.” About Avid Bioservices, Inc. Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com Contacts:Stephanie Diaz (Investors) Vida Strategic Partners415-675-7401 Tim Brons (Media)          Vida Strategic Partners 415-675-7402 Related Articles

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Avista Pharma Solutions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Avista Pharma Solutions is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Avista Pharma Solutions Patents

Avista Pharma Solutions has filed 15 patents.

The 3 most popular patent topics include:

  • Antiparasitic agents
  • Insecticides
  • Acetylcholinesterase inhibitors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/23/2019

9/15/2020

Insecticides, Acetylcholinesterase inhibitors, Antiparasitic agents, Organophosphate insecticides, Trifluoromethyl compounds

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/23/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/15/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Insecticides, Acetylcholinesterase inhibitors, Antiparasitic agents, Organophosphate insecticides, Trifluoromethyl compounds

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.